Rekombinanter KRT17 Antikörper (full length)

Produktnummer ABIN7878486

Der Kaninchen Monoklonal anti-KRT17 Antikörper wird verwendet zum Nachweis von KRT17 in Proben von Human. Er wurde validiert für IHC (p).

Kurzübersicht für Rekombinanter KRT17 Antikörper (full length) (ABIN7878486)

Target: KRT17 (Keratin 17 (KRT17))

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Monoklonal

Konjugat: Dieser KRT17 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: KRT17-7155R

Produktdetails anti-KRT17 Antikörper

Bindungsspezifität: full length

Verwendungszweck: Keratin 17 Antibody / Cytokeratin 17 / CK17 (azide and preservative free)

Aufreinigung: Protein A/G affinity

Immunogen: Recombinant full-length human KRT17 protein was used as the immunogen for the Keratin 17 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the Keratin 17 antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the Keratin 17 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Details zu KRT17

Target: KRT17 (Keratin 17 (KRT17))

Andere Bezeichnung: Keratin 17

Hintergrund: Cytokeratin 17 (CK17) is normally expressed in the basal cells ofcomplex epithelia but not in stratified orsimple epithelia. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glandssuch as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as epithelial stem cell marker because CK17 Ab marks basal cell differentiation. CK17 is expressed in SCLC much higher than in LADC. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. Additionally, anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.

UniProt: Q04695